Estimaciones de analistas de Wall Street para Lexaria Bioscience Corp. (LEXX): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 2 |
| Mantener | 0 |
| Venta | 0 |
| Venta fuerte | 0 |
| Analistas totales | 2 |
| Calificación media (1-5) | 1.00 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-10-28 | $-0.90 | ||
| 2026-07-13 | $-1.20 | $-0.90 | -33.3% |
| 2026-04-13 | $-0.90 | $-1.05 | +14.3% |
| 2026-01-13 | $-1.05 | $-1.95 | +46.2% |
| 2025-11-26 | $-2.10 | $-2.40 | +12.5% |
| 2025-07-14 | $-3.15 | $-2.25 | -40.0% |
| 2025-04-14 | $-2.25 | $-2.40 | +6.2% |
| 2025-01-10 | $-2.40 | $-1.80 | -33.3% |
Ratios de valoración
| Precio / Valor contable | 1.08 |
| EV / EBITDA | -0.43 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $40718 | $63639 | $433287 | $222610 | $384543 | $722738 | $255397 | $226208 | $464278 | $705923 |
| Coste de Ventas | $45615 | $29750 | $25185 | $22893 | $99378 | $175346 | $71841 | $31500 | $4822 | $2720 |
| Beneficio Bruto | -$4897 | $33889 | $408102 | $199717 | $215415 | $547392 | $183556 | $194708 | $459456 | $703203 |
| I+D | $9024 | $54185 | $492864 | $555730 | $387074 | $1.3M | $1.8M | $3.7M | $2.4M | $8.2M |
| Generales y Administrativos | $1.2M | $1.8M | $6.5M | $3.6M | $4.0M | $5.0M | $5.0M | $3.1M | $3.9M | $4.3M |
| Gastos Operativos | $1.2M | $1.9M | $7.0M | $4.3M | $4.4M | $6.2M | $6.8M | $6.7M | $6.2M | $12.6M |
| Beneficio Operativo | -$1.2M | -$1.9M | -$6.6M | -$4.1M | -$4.1M | -$5.7M | -$6.6M | -$6.5M | -$5.8M | -$11.9M |
| EBITDA | -$1.3M | -$1.9M | -$6.6M | -$4.0M | -$4.0M | -$4.0M | -$7.3M | -$6.6M | -$5.7M | -$11.8M |
| Gastos por Intereses | $2250 | $6015 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$1.3M | -$1.9M | -$6.6M | -$4.2M | -$4.1M | -$4.2M | -$7.4M | -$6.7M | -$5.8M | -$11.9M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$1.2M | -$1.9M | -$6.6M | -$4.1M | -$3.9M | -$4.0M | -$7.3M | -$6.7M | -$5.8M | -$11.9M |
| BPA | $-12.45 | $-14.25 | $-41.85 | $-24.30 | $-21.30 | $-13.80 | $-18.60 | $-15.15 | $-7.05 | $-9.90 |
| BPA Diluido | $-12.45 | $-14.25 | $-41.85 | $-24.30 | $-21.30 | $-13.80 | $-18.60 | $-15.15 | $-7.05 | $-9.90 |
| Acciones en Circulación (Diluidas) | $97422 | $130589 | $157688 | $172870 | $184892 | $292763 | $392350 | $440938 | $825598 | $1.2M |
Precio
| Precio | $3.10 |
| Capitalización | $5M |
| Bolsa | NASDAQ |
| País | CA |
Empresas relacionadas: ALLR · BCTX · CASI · CING · CLSD · CRIS · ENTO
Explorar sector: Healthcare · Biotechnology
Más secciones de LEXX: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones